LUNDBECK, NYCOMED
 
Learn More
 
 
Insomnia
 
Parkinson’s disease
 
Asthma/COPD
 
 
 
 
 
Neurim Pharmaceuticals Ltd  and H. Lundbeck A/S announced that Lundbeck in-licensed the exclusive rights for Circadin® for the treatment of primary insomnia for the majority of markets in Europe including the

five major markets. Furthermore, Lundbeck holds the exclusive option to evaluate commercialization in markets outside of Europe.

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company’s revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com



Copyright © Neurim Pharmaceuticals , Inc. All rights reserved.
 
Impresser Disclaimer Legal Site map